AbbVie Inc. (ABBV)
Analysts Estimate AbbVie (ABBV) to Report a Decline in Earnings: What to Look Out for
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
AbbVie: Strong Dividends But Humira Disappoints
Healthcare stocks are both defensive and present a mean reversion opportunity, making them attractive for risk-averse investors. Revenue exposure analysis shows consistent growth trends over 10 years, indicating stability and resilience but downward over 5. Valuation metrics show AbbVie to be only slightly undervalued based on FY 2025 projections.
AbbVie Secures FDA Approval for Parkinson's Disease Drug Vyalev
With the latest approval, ABBV's Vyalev becomes the first and only subcutaneous 24-hour infusion of levodopa-based therapy for treating advanced Parkinson's disease.
3 Growth Stocks That Could Be Bargain Buys Right Now
These stocks trade at less than 20 times their estimated future profits.
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know
AbbVie (ABBV) reachead $188.57 at the closing of the latest trading day, reflecting a -0.99% change compared to its last close.
Calls of the Day: Crowdstrike, Cheniere Energy, 3M, Abbott Labs, Abbvie and Eli Lilly
The Investment Committee debate the latest Calls Of The Day.
AbbVie wins FDA nod for infusion treatment for advanced Parkinson's disease
Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson's disease.
2 Magnificent Dividend Stocks to Buy and Hold Forever
These companies have compelling track records.
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the healthcare sector includes both small biotech firms working to develop specialized treatments and much larger, established companies engaging in a wide array of health-related operations.
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Buying these stocks gives you a great chance to beat the benchmark.
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
This Dividend King is beyond Buffett's reach to fully acquire and is a great pick for income investors.
